Search

Your search keyword '"Florido, Yanira"' showing total 15 results
Start Over Author "Florido, Yanira"
15 results on '"Florido, Yanira"'

1. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study

Author

Segura-Díaz, Adrián, additional, Stuckey, Ruth, additional, Florido, Yanira, additional, Sobas, Marta, additional, Alvarez-Larran, Alberto, additional, Ferrer, Francisca, additional, Pérez-Encinas, Manuel M, additional, Carreño-Tarragona, Gonzalo, additional, Fox, María Laura, additional, Tazón Vega, Barbara, additional, Cuevas, Barbara, additional, López Rodríguez, Juan Francisco, additional, Farías-Sánchez, Nuria, additional, González-Martín, Jesús M, additional, Gómez-Casares, María Teresa, additional, and Bilbao-Sieyro, Cristina, additional

Published
2024
Full Text
View/download PDF

2. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study

Author

Segura-Díaz, Adrián, primary, Stuckey, Ruth, additional, Florido, Yanira, additional, Sobas, Marta, additional, Álvarez-Larrán, Alberto, additional, Ferrer-Marín, Francisca, additional, Pérez-Encinas, Manuel, additional, Carreño-Tarragona, Gonzalo, additional, Fox, María Laura, additional, Vega, Barbara Tazón, additional, Cuevas, Beatriz, additional, Rodríguez, Juan Francisco López, additional, Farías-Sánchez, Nuria, additional, González-Martín, Jesús M., additional, Gómez-Casares, María Teresa, additional, and Bilbao-Sieyro, Cristina, additional

Published
2023
Full Text
View/download PDF

3. Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment

Author

Stuckey, Ruth, primary, Segura-Díaz, Adrián, additional, Sáez Perdomo, María Nieves, additional, Pérez Encinas, Manuel Mateo, additional, González San Miguel, Jóse David, additional, Florido, Yanira, additional, Sánchez-Sosa, Santiago, additional, López-Rodríguez, Juan Francisco, additional, Bilbao-Sieyro, Cristina, additional, and Gómez-Casares, María Teresa, additional

Published
2023
Full Text
View/download PDF

4. Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages

Author

Suárez-Cabrera, Alexia, primary, Fiallo-Suárez, Dolly Viviana, additional, Stuckey, Ruth, additional, Uroz-de la Iglesia, Marta Luna, additional, Florido, Yanira, additional, Lemes-Castellano, Angelina, additional, Perera-Álvarez, Miguel Ángel, additional, Luzardo-Henríquez, Hugo, additional, de la Nuez, Haridian, additional, Fernández-Caldas, Paula, additional, de la Iglesia, Silvia, additional, Gómez-Casares, María Teresa, additional, and Bilbao-Sieyro, Cristina, additional

Published
2022
Full Text
View/download PDF

5. Can the Gene Expression Profile of Patients with Acute Myeloid Leukemia Predict Complete Remission Following Induction Therapy?

Author

Sánchez-Sosa, Santiago, primary, Rodríguez-Medina, Carlos, additional, Stuckey, Ruth, additional, Florido, Yanira, additional, Santana, Guillermo, additional, González Martín, Jesús María, additional, Cruz-Cruz, Naylén, additional, Torres-Ochando, Melissa, additional, Fernández, Rosa, additional, Sánchez-Farías, Nuria, additional, Cionfrini, Antonia, additional, Labarta, Teresa Molero, additional, Gomez-Casares, María Teresa, additional, and Bilbao-Sieyro, Cristina, additional

Published
2022
Full Text
View/download PDF

6. Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Author

Pavlova, Sarka, Malcikova, Jitka, Radova, Lenka, Bonfiglio, Silvia, Cowland, Jack B., Brieghel, Christian, Andersen, Mette Klarskov, Karypidou, Maria, Biderman, Bella V, Doubek, Michael, Lazarian, Gregory, Rapado, Inmaculada, Vynck, Matthijs, Porret, Naomi, Andres, Martin, Rosenberg, Dina, Sahar, Dvora, Martinez-Laperche, Carolina, Borde, Ismael Buño, Hindley, Andrew, Sánchez, Julio Bravo, García-Marco, José, Serrano, Alicia, Ferrer Lores, Blanca, Fernández-Rodriguez, Concepción, Bellosillo, Beatriz, Stilgenbauer, Stephan, Tausch, Eugen, Nikdin, Hero, Quinn, Fiona, Atkinson, Emer, Van De Corput, Lisette, Yildiz, Cafer, Bilbao, Cristina, Florido, Yanira, Thiede, Christian, Schuster, Caroline, Stoj, Anastazja, Czekalska, Sylwia, Chatzidimitriou, Anastasia, Laidou, Stamatia, Bidet, Audrey, Dussiau, Charles, Nollet, Friedel, Piras, Giovanna, Borosova, Tereza, Kurucova, Terezia, Monne, Maria, Smirnova, Svetlana, Nikitin, Evgeny, Sloma, Ivan, Delfau, Marie-Helene, Largeaud, Laetitia, Ysebaert, Loic, Valk, Peter J. M., Christian, Amy, Walewska, Renata, Sebastião, Marta, da Silva, Maria Gomes, Galieni, Piero, Angelini, Mario, Rossi, Davide, Spina, Valeria, Matos, Sónia, Martins, Vânia, Donaldson, David, Stoklosa, Tomasz, Pepek, Monika, Baliakas, Panagiotis, Andreu, Rafa, Luna, Irene, Kahre, Tiina, Murumets, Ülle, Laird, Sophie, Ward, Daniel, Alcoceba, Miguel, Balanzategui, Ana, Scarfo, Lydia, Gandini, Francesca, Zapparoli, Ettore, Blanco, Adoracion, Costa, Pau Abrisqueta, Rodriguez, Ana E., Benito Sanchez, Maria Rocio, Davi, Frédéric, Bravetti, Clothilde, Gameiro, Paula, Martinez-Lopez, Joaquin, Tazon, Barbara, Baran-Marszak, Fanny, Davies, Zadie, Caterwood, Mark, Sudarikov, Andrey B, Rosenquist, Richard, Niemann, Carsten Utoft, Stamatopoulos, Kostas, Ghia, Paolo, and Pospisilova, Sarka

Published
2023
Full Text
View/download PDF

8. BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia

Author

Bilbao-Sieyro, Cristina, primary, Rodríguez-Medina, Carlos, additional, Florido, Yanira, additional, Stuckey, Ruth, additional, Sáez, María Nieves, additional, Sánchez-Sosa, Santiago, additional, González Martín, Jesús María, additional, Santana, Guillermo, additional, González-Pérez, Elena, additional, Cruz-Cruz, Naylén, additional, Fernández, Rosa, additional, Molero Labarta, Teresa, additional, and Gomez-Casares, María Teresa, additional

Published
2020
Full Text
View/download PDF

9. Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations

Author

Segura-Díaz, Adrián, primary, Stuckey, Ruth, additional, Florido, Yanira, additional, González-Martín, Jesús María, additional, López-Rodríguez, Juan Francisco, additional, Sánchez-Sosa, Santiago, additional, González-Pérez, Elena, additional, Sáez Perdomo, María Nieves Sáez, additional, Perera, María del Mar, additional, de la Iglesia, Silvia, additional, Molero-Labarta, Teresa, additional, Gómez-Casares, María Teresa, additional, and Bilbao-Sieyro, Cristina, additional

Published
2020
Full Text
View/download PDF

12. Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Author

Pavlova, Sarka, Malcikova, Jitka, Radova, Lenka, Bonfiglio, Silvia, Cowland, Jack B., Brieghel, Christian, Andersen, Mette Klarskov, Karypidou, Maria, Biderman, Bella V, Doubek, Michael, Lazarian, Gregory, Rapado, Inmaculada, Vynck, Matthijs, Porret, Naomi, Andres, Martin, Rosenberg, Dina, Sahar, Dvora, Martinez-Laperche, Carolina, Borde, Ismael Buño, Hindley, Andrew, Sánchez, Julio Bravo, García-Marco, José, Serrano, Alicia, Ferrer Lores, Blanca, Fernández-Rodriguez, Concepción, Bellosillo, Beatriz, Stilgenbauer, Stephan, Tausch, Eugen, Nikdin, Hero, Quinn, Fiona, Atkinson, Emer, Van De Corput, Lisette, Yildiz, Cafer, Bilbao, Cristina, Florido, Yanira, Thiede, Christian, Schuster, Caroline, Stoj, Anastazja, Czekalska, Sylwia, Chatzidimitriou, Anastasia, Laidou, Stamatia, Bidet, Audrey, Dussiau, Charles, Nollet, Friedel, Piras, Giovanna, Borosova, Tereza, Kurucova, Terezia, Monne, Maria, Smirnova, Svetlana, Nikitin, Evgeny, Sloma, Ivan, Delfau, Marie-Helene, Largeaud, Laetitia, Ysebaert, Loic, Valk, Peter J. M., Christian, Amy, Walewska, Renata, Sebastião, Marta, da Silva, Maria Gomes, Galieni, Piero, Angelini, Mario, Rossi, Davide, Spina, Valeria, Matos, Sónia, Martins, Vânia, Donaldson, David, Stoklosa, Tomasz, Pepek, Monika, Baliakas, Panagiotis, Andreu, Rafa, Luna, Irene, Kahre, Tiina, Murumets, Ülle, Laird, Sophie, Ward, Daniel, Alcoceba, Miguel, Balanzategui, Ana, Scarfo, Lydia, Gandini, Francesca, Zapparoli, Ettore, Blanco, Adoracion, Costa, Pau Abrisqueta, Rodriguez, Ana E., Benito Sanchez, Maria Rocio, Davi, Frédéric, Bravetti, Clothilde, Gameiro, Paula, Martinez-Lopez, Joaquin, Tazon, Barbara, Baran-Marszak, Fanny, Davies, Zadie, Caterwood, Mark, Sudarikov, Andrey B, Rosenquist, Richard, Niemann, Carsten Utoft, Stamatopoulos, Kostas, Ghia, Paolo, and Pospisilova, Sarka

Abstract

The presence of mutations in the TP53gene is a powerful prognostic and predictive marker in chronic lymphocytic leukemia (CLL). Widespread use of NGS has enabled the detection of variants ≤10 % variant allelic frequency (low-VAF variants); however, the overall reliability and reproducibility of NGS techniques to identify such variants have been questioned repeatedly. Individual studies using sensitive, custom NGS-based assays have mostly demonstrated the shortened overall survival (OS) and event-free survival in patients with low-VAF TP53variants treated with chemoimmunotherapy (CIT) regimens with median survival ranging between that of TP53 variants >10 % VAF (high-VAF) and wild-type TP53(wt- TP53).

Published
2023
Full Text
View/download PDF

13. Surfactant protein A genetic variants associate with severe respiratory insufficiency in pandemic influenza A virus infection

Author

Herrera-Ramos, Estefanía, primary, López-Rodríguez, Marta, additional, Ruíz-Hernández, José, additional, Horcajada, Juan, additional, Borderías, Luis, additional, Lerma, Elisabeth, additional, Blanquer, José, additional, Pérez-González, María, additional, García-Laorden, María, additional, Florido, Yanira, additional, Mas-Bosch, Virginia, additional, Montero, Milagro, additional, Ferrer, José, additional, Sorlí, Luisa, additional, Vilaplana, Carlos, additional, Rajas, Olga, additional, Briones, Marisa, additional, Aspa, Javier, additional, López-Granados, Eduardo, additional, Solé-Violán, Jordi, additional, de Castro, Felipe, additional, and Rodríguez-Gallego, Carlos, additional

Published
2014
Full Text
View/download PDF

14. The Fcγ receptor IIA-H/H131 genotype is associated with bacteremia in pneumococcal community-acquired pneumonia*

Author

Solé-Violán, Jordi, primary, García-Laorden, M. Isabel, additional, Marcos-Ramos, José Alberto, additional, Rodríguez de Castro, Felipe, additional, Rajas, Olga, additional, Borderías, Luis, additional, Briones, M. Luisa, additional, Herrera-Ramos, Estefanía, additional, Blanquer, José, additional, Aspa, Javier, additional, Florido, Yanira, additional, García-Bello, Miguel Angel, additional, Ferrer-Agüero, José María, additional, Sologuren, Ithaisa, additional, and Rodriguez-Gallego, Carlos, additional

Published
2011
Full Text
View/download PDF

15. Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

Author

Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland JB, Brieghel C, Andersen MK, Karypidou M, Biderman B, Doubek M, Lazarian G, Rapado I, Vynck M, Porret NA, Andres M, Rosenberg D, Sahar D, Martínez-Laperche C, Buño I, Hindley A, Donaldson D, Sánchez JB, García-Marco JA, Serrano-Alcalá A, Ferrer-Lores B, Fernández-Rodriguez C, Bellosillo B, Stilgenbauer S, Tausch E, Nikdin H, Quinn F, Atkinson E, van de Corput L, Yildiz C, Bilbao-Sieyro C, Florido Y, Thiede C, Schuster C, Stoj A, Czekalska S, Chatzidimitriou A, Laidou S, Bidet A, Dussiau C, Nollet F, Piras G, Monne M, Smirnova S, Nikitin E, Sloma I, Claudel A, Largeaud L, Ysebaert L, Valk PJM, Christian A, Walewska R, Oscier D, Sebastião M, da Silva MG, Galieni P, Angelini M, Rossi D, Spina V, Matos S, Martins V, Stokłosa T, Pepek M, Baliakas P, Andreu R, Luna I, Kahre T, Murumets Ü, Pikousova T, Kurucova T, Laird S, Ward D, Alcoceba M, Balanzategui A, Scarfo L, Gandini F, Zapparoli E, Blanco A, Abrisqueta P, Rodríguez-Vicente AE, Benito R, Bravetti C, Davi F, Gameiro P, Martinez-Lopez J, Tazón-Vega B, Baran-Marszak F, Davis Z, Catherwood M, Sudarikov A, Rosenquist R, Niemann CU, Stamatopoulos K, Ghia P, and Pospisilova S

Abstract

In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using their NGS method of choice. The sensitivity was 85.6%, 94.5%, and 94.8% at 1%, 2%, and 3% VAF cut-off, respectively. While only one false positive (FP) result was reported at >2% VAF, it was more challenging to distinguish true variants <2% VAF from background noise (37 FPs reported by 9 laboratories). The impact of low-VAF variants on time-to-second-treatment (TTST) and overall survival (OS) was investigated in a series of 1092 patients. Among patients not treated with targeted agents, patients with low-VAF TP53 variants had shorter TTST and OS versus wt- TP53 patients, and the relative risk of second-line treatment or death increased continuously with increasing VAF. Targeted therapy in ≥2 line diminished the difference in OS between patients with low-VAF TP53 variants and wt- TP53 patients, while patients with high-VAF TP53 variants had inferior OS compared to wild type- TP53 cases. Altogether, NGS-based approaches are technically capable of detecting low-VAF variants. No strict threshold can be suggested from a technical standpoint, laboratories reporting TP53 mutations should participate in a standardized validation set-up. Finally, whereas low-VAF variants affected outcomes in patients receiving chemoimmunotherapy, their impact on those treated with novel therapies remains undetermined. Our results pave the way for the harmonized and accurate TP53 assessment, which is indispensable for elucidating the role of TP53 mutations in targeted treatment., Competing Interests: Bárbara Tazón‐Vega: Honoraria: Bristol Meyer Squibb. Beatriz Bellosillo: Advisory board honoraria, research support, travel support, speaker fees: Astra‐Zeneca, BMS, Janssen, Merck‐Serono, Novartis, Pfizer, Hoffman‐La Roche, ThermoFisher. Christian Brieghel: Travel grant: Octapharma. Carsten U. Niemann: Research funding and/or consultancy fees: Abbvie, AstraZeneca, Beigene, Janssen, Genmab, Lilly, MSD, CSL Behring, Takeda, Octapharma. Davide Rossi: Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Janssen, Lilly. Research grants: AbbVie, AstraZeneca, Janssen. Travel grants: AstraZeneca, Janssen. Eugen Tausch: Honoraria and research support: Abbvie, AstraZeneca, BeiGene, Janssen, Hoffmann‐La Roche; Research support from Abbvie, Roche, Gilead. Frédéric Davi: Honoraria: Janssen, AstraZeneca. Kostas Stamatopoulos: Research funding, honoraria and/or consultancy fees: Abbvie, AstraZeneca, Janssen, Lilly, Roche. Lydia Scarfo: Consultancy: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly; Speaker Bureau: Octapharma. Miguel Alcoceba: Honoraria and travel grants: Janssen, AstraZeneca. Martin Andres: Consultancy, Honoraria, and travel support: AstraZeneca, Novartis, Roche, Janssen‐Cilag. Maria Gomes da Silva: Consultancy and Research Funding: Janssen Cilag, AstaZeneca, Abbvie, Roche, Takeda. Pau Abrisqueta: Consultancy and Honoraria: Janssen, Abbvie, Roche, BMS, AstraZeneca, Genmab. Panagiotis Baliakas: Honoraria: Abbvie, Gilead, Janssen. Research funding: Gilead. Paolo Ghia: Honoraria: AbbVie, Astrazeneca, BeiGene, BMS, Galapagos, Janssen, Lilly/Loxo Oncology, MSD, Roche. Research funding: AbbVie, AstraZeneca, BMS, Janssen. Richard Rosenquist: Honoraria: AbbVie, AstraZeneca, Janssen, Illumina, Roche. Renata Walewska: Travel support: AbbVie, AstraZeneca, Janssen, Beigene. Sylwia Czekalska: Honoraria: AstraZeneca. Funding: Janssen, AstraZeneca. Stephan Stilgenbauer: Advisory board honoraria, research support, travel support, speaker fees: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, BMS, Celgene, Gilead, GSK, Hoffmann‐La Roche, Infinity, Janssen, Lilly, Novartis, Sunesis, Verastem. Tiina Kahre: Honoraria: AstraZeneca. Tomasz Stokłosa: Honoraria and Research Funding: Janssen, AstraZeneca. The remaining authors have no competing interests to declare., (© 2025 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results